(Q34579745)

3 August 2017

title

Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. (English)

1 reference

3 August 2017

5

Mark Pimentel

1 reference

3 August 2017

Janet Yang

1

1 reference

3 August 2017

Hyo-Rang Lee

series ordinal

2

1 reference

3 August 2017

Kimberly Low

series ordinal

3

1 reference

3 August 2017

Soumya Chatterjee

series ordinal

4

1 reference

3 August 2017

publication date

23 May 2007

1 reference

Digestive Diseases and Sciences

3 August 2017

published in

1 reference

3 August 2017

volume

53

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

169-174

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-007-9839-8

3 August 2017

exact match

0 references

cites work

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-007-9839-8

A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-007-9839-8

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial

21 January 2018

1 reference

12 December 2020

Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial

1 reference

12 December 2020

Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.

1 reference

12 December 2020

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative

1 reference

12 December 2020

Functional bowel disorders in apparently healthy people

1 reference

12 December 2020

Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria

1 reference

12 December 2020

Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth.

1 reference

12 December 2020

The irritable bowel syndrome: a paroxysmal motor disorder.

1 reference

12 December 2020

Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.

1 reference

12 December 2020

Malabsorption in jejunal diverticulosis treated with resection of the diverticula

1 reference

12 December 2020

Regional cerebral activity in normal and pathological perception of visceral pain.

1 reference

12 December 2020

Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment

1 reference

12 December 2020

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections

1 reference

12 December 2020

Irritable bowel syndrome: a technical review for practice guideline development

1 reference

12 December 2020

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

1 reference

12 December 2020

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

1 reference

12 December 2020

Diarrhea and malabsorption in the elderly

1 reference

12 December 2020

Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.

1 reference

12 December 2020

Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction

1 reference

12 December 2020

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential

1 reference

12 December 2020

Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma.

1 reference

12 December 2020

Functional bowel disorders

1 reference

12 December 2020

Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study

1 reference

12 December 2020

10.1007/S10620-007-9839-8

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1041720089

0 references

1 reference